SCHEMBL16636390

SCHEMBL16636390

COC(=O)[C@@H]1CCCC[C@H]1c1csc(C2CCOCC2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 1/20 0.39
CNR2 P34972 2/20 0.39
CPT2 P23786 1/20 0.33
CPT1A P50416 1/20 0.33
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
ALDH1A1 P00352 3/20 0.32
UCHL1 P09936 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
TMIGD3 P0DMS9 2/20 0.31
ADORA1 P30542 2/20 0.31
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31
HSD17B10 Q99714 1/20 0.31
GRM5 P41594 1/20 0.31
TAS1R3 Q7RTX0 1/20 0.31
TAS1R1 Q7RTX1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16636392 1.00 SLC6A2 (0.39) SLC6A2SLC6A4CNR2CPT2CPT1A
SCHEMBL16636034 0.85 ALDH1A1 (0.37) CNR2ALDH1A1UCHL1SMN1; SMN2TMIGD3
SCHEMBL16636564 0.84 SLC6A2 (0.39) SLC6A2SLC6A4CNR2CPT2CPT1A
SCHEMBL16636565 0.84 SLC6A2 (0.39) SLC6A2SLC6A4CNR2CPT2CPT1A
SCHEMBL16636099 0.79 SLC6A2 (0.45) SLC6A2SLC6A4CNR2CPT2CPT1A
SCHEMBL16635704 0.76 SLC6A2 (0.36) SLC6A2SLC6A4CNR2CPT2CPT1A
SCHEMBL16635706 0.76 SLC6A2 (0.36) SLC6A2SLC6A4CNR2CPT2CPT1A
SCHEMBL31705893 0.72 MAOA (0.40) CNR2NPC1RAB9ASMN1; SMN2GRM5
SCHEMBL16635935 0.71 SLC6A2 (0.49) SLC6A2SLC6A4CNR2CPT2CPT1A
SCHEMBL16635933 0.71 SLC6A2 (0.49) SLC6A2SLC6A4CNR2CPT2CPT1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ SLC6A2 4308/4885SLC6A4 4386/4885CNR2 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.